EFSA Journal (Jun 2021)
Safety and efficacy of a feed additive consisting of an essential oil from the leaves of Citrus × aurantium L. (petitgrain bigarade oil) for use in all animal species (FEFANA asbl)
Abstract
Abstract Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of an essential oil from the leaves of Citrus x aurantium L. (petitgrain bigarade oil), when used as a sensory additive (flavouring) in feed and water for drinking for all animal species. The FEEDAP Panel concluded that the essential oil under assessment is safe up to the maximum proposed use level of 125 mg/kg complete feed for ornamental fish. For the other species, the calculated safe concentrations in complete feed are 10 mg/kg for chicken for fattening, 14 mg/kg for laying hen, 13 mg/kg for turkey for fattening, 17 mg/kg for piglet, 20 mg/kg for pig for fattening, 25 mg/kg for lactating sow, 43 mg/kg for veal calf (milk replacer), 38 mg/kg for cattle for fattening, sheep, goat and horse, 24 mg/kg for dairy cow, 15 mg/kg for rabbit, 42 mg/kg for salmon, 44 mg/kg for dog and 8 mg/kg for cat. The FEEDAP Panel considered that the use level in water for drinking is safe provided that the total daily intake of the additive does not exceed the daily amount that is considered safe when consumed via feed. Simultaneous use in feed and water for drinking may lead to the maximum safe dose being exceeded. No concerns for consumer safety were identified following the use of the additive up to the highest safe level in feed. The essential oil under assessment should be considered as irritant to skin, eyes and the respiratory tract, and as a skin sensitiser. The use of the additive in animal feed under the proposed conditions was not expected to pose a risk for the environment. Petitgrain bigarade oil was recognised to flavour food. Since its function in feed would be essentially the same as that in food, no further demonstration of efficacy was considered necessary.
Keywords